My key projects

Digital Healthcare

Digital Companion launch together with Pharma partners

At Sidekick Health we developed companion apps in Atopic Dermatitis, Rheumatoid Arthritis, and Breast Cancer. We co-created with our global and local Pharma partner teams the go-to-market strategies, and launch plans. Launch and promotional activities were executed by our team in multiple EU markets. User adoption, as a critical KPI was constantly tracked and improved.

EMA approved Rx+DTx Launch in Asthma

Novartis Pharma and Propeller Health co-developed a digital companion for the Breezhaler portfolio. Enerzair Breezhaler was approved by EMA with the digital companion. We established a strategic partnership with cross-divisional teams on both sides, delivering jointly the sensor and app, the EMA submission file, and the local market distribution. Global and local Novartis teams worked closely on the pioneering launch, supported by senior management as a first digital lighthouse project at Novartis.

pDTx (DiGA) launch in ADHD

MEDICE Pharma developed and launched the first DiGA in ADHD - a digital parent training for parents of kids with ADHD. I led the launch preparation including the hiToco brand strategy, launch plan, market research, and all promotional pre-launch activities. An innovative launch event with exceptional customer feedback topped the cross-functional preparation.

Cancer platform expansion to Europe

I assisted an American start-up, running a cancer community platform in the US, with the acquisition of a German cancer DTx and the development of an EU market entry strategy.

Establish a hybrid eco-system for citizens with respiratory diseases

Lovexair foundation is a patient serving, holistic service provider building a learning community. We are an international non-profit organization and innovative healthcare advocates. As we believe in leveraging technology for better and equal patient care, we develop a validated hybrid eco-system delivering clinical and social care. Lovexair is a partner of EHTEL and HIMSS providing the civic perspective on digital health and the European Health Data Space (EHDS).

Exacerbation risk prediction

AC-DC: Asthma COPD Disease Classification

At Novartis Pharma we developed, tested and patented an AI/ML enabled algorithm that allows physicians to perform a differential diagnosis of asthma and COPD. Oversight and input were provided by chairman and committees of GOLD and GINA guidelines. ACDC delivered a superior diagnostic accuracy compared to physicians.

Reducing exacerbations in COPD to avoid hospitalization can reduce healthcare cost. At Novartis we developed an algorithm to predict the risk of an upcoming exacerbation and developed a business model for the US.

Asthma Virtual Health Assistant

Together with the LoveXair Foundation we developed Altys - a virtual health assistant for asthma patients. The App aimed to help people managing their asthma more easily and to increase treatment plan adherence. We focused on sustainable behaviour change by addressing identified patient personas based on the SPUR (Social - Psychological - Usage - Rational) behavioural diagnostic tool developed by Observia.

Mobile Spirometer

Novartis Pharma distributed NuvoAir's AirSmart spirometry technology to physicians worldwide. We aimed to address the unmet medical needs of respiratory patients by increasing the number of lung function tests via the easy to use & access mobile spirometer.

Pharma Marketing

Drug launches

1. Launch an inhaled Asthma drug together with a digital companion as Global Head Digital Solutions.

2. Launch Digital Companions with Pharma partner drugs in Europe.

3. Launch one inhaled COPD and one heart failure product in Malaysia as Business Franchise Head.

4. Be Asian Cluster lead for heart failure launches in the region.

5. Launch three inhaled COPD products, leading a cross-functional team in Germany as Brand Director.

6. Launch new indications in local markets.

Commercial projects

1. Manage P&L for drug portfolio and Business Franchise.

2. Organize innovative and inspiring Cycle Meetings in Germany, Greece and Malaysia.

3. Organize impactful customer events, like launch meetings or annual scientific events.

4. Develop strategy for generic defense at times of loss of exclusivity.

5. Develop emotional and differentiating promotional materials, like Faces of COPD.

6. Run patient campaigns, like Lauffeuer für COPD, collecting steps for patients with COPD.

7. Establish a digital patient council to co-develop digital health solutions

Life Science Leadership

• International Senior Life Science Executive

• P&L management for drug portfolio and Business Franchise

• Cross-functional leadership (Marketing, Sales, Medical, Digital, Regulatory, Market Access, Finance, Communication)

• Global and regional leadership

• Life Science Corporate, Healthcare Start-up and Consulting

• Non-executive director

• Mentor

Interim Management

• Interim CEO - Healthcare Start-up:
  Manage transition into MEDICE organisation, develop portfolio strategy, reduce monthly run rate, reduce team size and sharpen role profiles

• Interim Marketing Director - pDTx (DiGA) Launch
  Lead launch team and launch preparation in a mix of Global and Local Marketing role.